Literature DB >> 31580018

[The efficacy of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps: a discussion of 2 refractory cases].

Peter Jandus1, Thomas Harr1, Michael B Soyka2, Basile Nicolas Landis3.   

Abstract

Nasal polyposis is a specific phenotype of chronic rhinosinusitis (CRS). Some cases can be managed with topical and infrequent use of systemic steroids, while many patients require surgery. Despite postoperative, regular steroid administration, recurrences may be found especially in patients suffering from Aspirin exacerbated respiratory disease (AERD), a particularly severe form of CRS with polyps, asthma and non-steroid-anti-inflammatory-drug (NSAID) intolerance. We report two cases of difficult-to-treat AERD patients following revision surgery, treated with monoclonal anti-IgE antibody (omalizumab) and successful control of the disease and symptoms. Omalizumab may be a promising alternative in selected cases of CRS with nasal polyps to avoid overuse of systemic steroids and frustrating repetition of paranasal sinus surgeries.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31580018

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  1 in total

1.  Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients.

Authors:  Francesco Bandi; Stefania Gallo; Andrea Preti; Francesco Mozzanica; Dina Visca; Margherita Marelli; Enrico Maddalone; Cinzia Gambarini; Adriano Vaghi; Antonio Spanevello; Paolo Castelnuovo
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-12       Impact factor: 2.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.